Pharmaceutical Pricing Practices, Utilization and Costs - Meeting Summary. III. Pharmaceutical Utilization Issues


The third session of the conference explored changing trends in the utilization of prescription drugs, the effects of health insurance on utilization, and questions pertaining to the value of prescription drug utilization and expenditures. The session opened with four formal presentations:

  • Cindy Parks Thomas, Ph.D., Schneider Institute for Health Policy, Brandeis University presented data on changes in utilization and costs of prescription drugs in three therapeutic classes.
  • Nancy Ostrove, Ph.D., Center for Drug Evaluation and Research, FDA, reported on the FDA's role in regulating consumer advertising of prescription drugs and on FDA's recent research on consumer-directed advertising of prescription drugs.
  • John Poisal, Office of Strategic Planning, Health Care Financing Administration (HCFA(now known as CMS)), reported recent findings regarding prescription drug utilization among Medicare beneficiaries from HCFA(now known as CMS)'s Medicare Current Beneficiary Survey.
  • Bruce Stuart, Ph.D., Peter Lamy Center for Drug Therapy and Aging, School of Pharmacy, University of Maryland, presented a framework for maximizing the value from prescription drug therapy.

The session also included a Panel Discussion and a discussion of Research Questions.